PharmExec
CONTINUE TO SITE >

OR WAIT 15 SECS

Pharmaceutical Executive
Spotlight
Topic
News
Media
Publications
Resources
Brand Insights
Subscribe

  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.

Spotlight
  • Pharmaceutical Executive APEX Awards
  • Leadership During the Pandemic
TopicSee All >
  • Executive Profiles
  • R&D/Clinical Trials
  • Strategy
  • Supply Chain
  • Technology
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.

CPhI Annual Report Looks at Next 5 years

September 18, 2018

Pharmaceutical Executive

CPhI Worldwide-organized by UBM (part of Informa PLC)- released part two of its annual report, evaluating the effects of regulatory diligence, trade agreements, and IP rights over the next five years. Two annual report experts believe that IPRs and trade agreements and regulator divergence could potentially have profound global impacts.

The full findings of the CPhI Annual Report include 12 in-depth expert contributions as well as the CPhI Manufacturing and Bio leagues tables, which will evaluate the relative reputations of each major pharma country. 

To view the report, click here.

 

 

Related Content:

News